1 |
Zhang HP, Sun YL, Wang YF, Yazici D, Azkur D, Ogulur I, Azkur AK, Yang ZW, Chen XX, Zhang AZ, Hu JQ, Liu GH, Akdis M, Akdis CA, Gao YD. Recent developments in the immunopathology of COVID-19. Allergy 2023;78:369-88. [PMID: 36420736 DOI: 10.1111/all.15593] [Reference Citation Analysis]
|
2 |
Puthanakit T, Nantanee R, Jaru-ampornpan P, Chantasrisawad N, Sophonphan J, Meepuksom T, Jupimai T, Sodsai P, Anugulruengkitt S, Hirankarn N. Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents. Vaccine: X 2022;12:100211. [DOI: 10.1016/j.jvacx.2022.100211] [Reference Citation Analysis]
|
3 |
Puthanakit T, Chantasrisawad N, Yoohat K, Nantanee R, Sophonphan J, Meepuksom T, Sodsai P, Phanthanawiboon S, Jantarabenjakul W, Hirankarn N, Kosalaraksa P. Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents. Vaccines (Basel) 2022;10:1646. [PMID: 36298510 DOI: 10.3390/vaccines10101646] [Reference Citation Analysis]
|
4 |
Chantasrisawad N, Puthanakit T, Kornsitthikul K, Jaru-ampornpan P, Tawan M, Matapituk P, Sophonphan J, Anugulruengkitt S, Tangsathapornpong A, Katanyutanon A. Immunogenicity to SARS-CoV-2 Omicron variant among school-aged children with 2-dose of inactivated SARS-CoV-2 vaccines followed by BNT162b2 booster. Vaccine: X 2022. [DOI: 10.1016/j.jvacx.2022.100221] [Reference Citation Analysis]
|